Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Targeting p38α Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells.

Cánovas B, Igea A, Sartori AA, Gomis RR, Paull TT, Isoda M, Pérez-Montoyo H, Serra V, González-Suárez E, Stracker TH, Nebreda AR.

Cancer Cell. 2018 Jun 11;33(6):1094-1110.e8. doi: 10.1016/j.ccell.2018.04.010. Epub 2018 May 24.

PMID:
29805078
2.

Regulation of Mammary Luminal Cell Fate and Tumorigenesis by p38α.

Del Barco Barrantes I, Stephan-Otto Attolini C, Slobodnyuk K, Igea A, Gregorio S, Gawrzak S, Gomis RR, Nebreda AR.

Stem Cell Reports. 2018 Jan 9;10(1):257-271. doi: 10.1016/j.stemcr.2017.11.021. Epub 2017 Dec 28.

3.

Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population.

Gómez-Miragaya J, Palafox M, Paré L, Yoldi G, Ferrer I, Vila S, Galván P, Pellegrini P, Pérez-Montoyo H, Igea A, Muñoz P, Esteller M, Nebreda AR, Urruticoechea A, Morilla I, Pernas S, Climent F, Soler-Monso MT, Petit A, Serra V, Prat A, González-Suárez E.

Stem Cell Reports. 2017 May 9;8(5):1392-1407. doi: 10.1016/j.stemcr.2017.03.026. Epub 2017 Apr 27.

4.

Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer.

Jaeger S, Igea A, Arroyo R, Alcalde V, Canovas B, Orozco M, Nebreda AR, Aloy P.

Cancer Res. 2017 Jan 15;77(2):459-469. doi: 10.1158/0008-5472.CAN-16-0097. Epub 2016 Nov 22.

5.

Chronic p53-independent p21 expression causes genomic instability by deregulating replication licensing.

Galanos P, Vougas K, Walter D, Polyzos A, Maya-Mendoza A, Haagensen EJ, Kokkalis A, Roumelioti FM, Gagos S, Tzetis M, Canovas B, Igea A, Ahuja AK, Zellweger R, Havaki S, Kanavakis E, Kletsas D, Roninson IB, Garbis SD, Lopes M, Nebreda A, Thanos D, Blow JJ, Townsend P, Sørensen CS, Bartek J, Gorgoulis VG.

Nat Cell Biol. 2016 Jul;18(7):777-89. doi: 10.1038/ncb3378. Epub 2016 Jun 20.

6.

Essential role of the Cdk2 activator RingoA in meiotic telomere tethering to the nuclear envelope.

Mikolcevic P, Isoda M, Shibuya H, del Barco Barrantes I, Igea A, Suja JA, Shackleton S, Watanabe Y, Nebreda AR.

Nat Commun. 2016 Mar 30;7:11084. doi: 10.1038/ncomms11084.

7.

Global Analysis of CPEBs Reveals Sequential and Non-Redundant Functions in Mitotic Cell Cycle.

Giangarrà V, Igea A, Castellazzi CL, Bava FA, Mendez R.

PLoS One. 2015 Sep 23;10(9):e0138794. doi: 10.1371/journal.pone.0138794. eCollection 2015.

8.

The Stress Kinase p38α as a Target for Cancer Therapy.

Igea A, Nebreda AR.

Cancer Res. 2015 Oct 1;75(19):3997-4002. doi: 10.1158/0008-5472.CAN-15-0173. Epub 2015 Sep 16. Review.

9.

Targeting of non-oncogene addiction.

Igea A, Gupta J, Nebreda AR.

Aging (Albany NY). 2015 Aug;7(8):525-6. No abstract available.

PMID:
26298432
Free PMC Article
10.

Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.

Gupta J, Igea A, Papaioannou M, Lopez-Casas PP, Llonch E, Hidalgo M, Gorgoulis VG, Nebreda AR.

Oncotarget. 2015 Apr 20;6(11):8539-51.

11.

Dual function of p38α MAPK in colon cancer: suppression of colitis-associated tumor initiation but requirement for cancer cell survival.

Gupta J, del Barco Barrantes I, Igea A, Sakellariou S, Pateras IS, Gorgoulis VG, Nebreda AR.

Cancer Cell. 2014 Apr 14;25(4):484-500. doi: 10.1016/j.ccr.2014.02.019. Epub 2014 Mar 27.

12.

Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK.

Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR.

EMBO Mol Med. 2013 Nov;5(11):1759-74. doi: 10.1002/emmm.201302732. Epub 2013 Sep 24.

13.

Multi-phosphorylation of the intrinsically disordered unique domain of c-Src studied by in-cell and real-time NMR spectroscopy.

Amata I, Maffei M, Igea A, Gay M, Vilaseca M, Nebreda AR, Pons M.

Chembiochem. 2013 Sep 23;14(14):1820-7. doi: 10.1002/cbic.201300139. Epub 2013 Jun 6.

PMID:
23744817
14.

Lipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism.

Pérez Y, Maffei M, Igea A, Amata I, Gairí M, Nebreda AR, Bernadó P, Pons M.

Sci Rep. 2013;3:1295. doi: 10.1038/srep01295.

15.

Expression and functional validation of new p38α transcriptional targets in tumorigenesis.

Swat A, Dolado I, Igea A, Gomez-Lopez G, Pisano DG, Cuadrado A, Nebreda AR.

Biochem J. 2011 Mar 15;434(3):549-58. doi: 10.1042/BJ20101410.

PMID:
21226672
16.

Meiosis requires a translational positive loop where CPEB1 ensues its replacement by CPEB4.

Igea A, Méndez R.

EMBO J. 2010 Jul 7;29(13):2182-93. doi: 10.1038/emboj.2010.111. Epub 2010 Jun 8.

17.

Long-term follow-up of atrial fibrillation patients in the NASPEAF study. Prospective evaluation of different antiplatelet treatments.

Bover R, Pérez-Gómez F, Maluenda MP, Asenjo S, Pérez-Saldaña R, Igea A, Suárez M, Coleto D, Fernández C.

Rev Esp Cardiol. 2009 Sep;62(9):992-1000. English, Spanish.

18.

New derivatives of 5-nitroimidazole: synthesis and antiparasitic activity.

Alcalde E, Maños L, Dinares I, Valls N, Elguero J, Escario JA, Martinez AR, Igea A, Osuna A, Ruiz-Perez LM, et al.

Farmaco. 1989 Nov;44(11):1095-107.

PMID:
2701965
19.

Antiparasitic activity of nine pyrazole derivatives against Trichomonas vaginalis, Entamoeba invadens and Plasmodium berghei.

Escario JA, Igea AM, Contreras M, Martinez-Fernandez AR, Claramunt R, Lopez C.

Ann Trop Med Parasitol. 1988 Jun;82(3):257-62.

PMID:
3074738

Supplemental Content

Support Center